Immune stimulant molecule shown to prevent cancer

Immune checkpoint stimulator, SA-4-1BBL, as a single agent prevents against multiple types of cancer

LOUISVILLE, Ky. – A research team at the University of Louisville has discovered that an immune checkpoint molecule they developed for cancer immunotherapy, also protects against future development of multiple types of cancer when administered by itself.

The recombinant protein molecule SA-4-1BBL has been used to enhance the therapeutic efficacy of cancer vaccines with success in pre-clinical animal models. It accomplishes this by boosting the effectiveness of CD8+ T cells, adaptive immune cells trained to target the tumor for destruction. Surprisingly, when the researchers treated normal healthy mice with SA-4-1BBL alone, the mice were protected when the researchers later exposed them to different types of tumor cells.

“The novelty we are reporting is the ability of this molecule to generate an immune response that patrols the body for the presence of rare tumor cells and to eliminate cancer before it takes hold in the body,” said Haval Shirwan, Ph.D., professor in the UofL Department of Microbiology and Immunology and the UofL Institute for Cellular Therapeutics. “Generally, the immune system will need to be exposed to the tumor, recognize the tumor as dangerous, and then generate an adaptive and tumor-specific response to eliminate the tumor that it recognizes. Thus, our new finding is very surprising because the immune system has not seen a tumor, so the response is not to the presence of a tumor.”

The researchers have determined that the molecule generates a tumor immune surveillance system through activation of what are known as CD4+ T cells and innate NK cells, thereby protecting the mice against various cancer types they have never had. This function is an indication of the molecule’s effectiveness in cancer immunoprevention.

In the research, published today in Cancer Research, mice that had never had cancer were treated with SA-4-1BBL alone, then challenged with cervical and lung cancer tumor cells at various time intervals. The mice showed significant protection against tumor development, with the greatest protection when challenged two weeks after treatment with SA-4-1BBL. The cancer immunoprevention effect generated by SA-4-1BBL lasted more than eight weeks.

“Just giving SA-4-1BBL alone prevents the formation of tumors in animal models,” Shirwan said. “To our knowledge, this is the first study to demonstrate that an immune checkpoint stimulator, known for its function for adaptive immunity, as a single agent can activate an immune system surveillance mechanism for protection against various tumor types.”

Additional testing showed that CD8+ T cells were not required for the protection, but when CD4+ T and NK cells were eliminated in the mice, protection failed, indicating these two cell types were necessary to achieve the effect. The lack of necessity for CD8+ T cells indicates the process is not one of conventional acquired immunity.

Although the research, which was conducted in collaboration with FasCure Therapeutics, LLC, tested the mice for cervical and lung cancers, the protective function of SA-4-1BBL works without context of specific tumor antigens, giving it the potential to be effective in preventing any number of tumor types.

“We are very excited about the cancer immunoprevention possibilities of this molecule. Its effectiveness is not tumor specific, and as a natural ligand, it does not cause toxicity, as is found with 4-1BB agonist antibodies. Plus, the fear of autoimmunity is highly minimized, as evident from our data, because it is activating the innate immune cells,” said Esma Yolcu, Ph.D., associate professor at UofL and co-author of the study.

Immune checkpoint stimulators and inhibitors are major regulators of the immune system and work in a similar fashion to the “brake” and “gas” pedals in a vehicle. Cancer evades the immune system by various means, including immune checkpoint inhibitors, which apply the brake on the immune response against a tumor. Stimulators, on the other hand, serve the accelerator function, improving immune responses against cancer.

Drugs to block the action of immune checkpoint inhibitors already have shown therapeutic efficacy for several cancer types in the clinic and are approved by the Food and Drug Administration (FDA). According to Shirwan, the focus now is on immune checkpoint stimulators.

“Several antibody molecules are in clinical testing for cancer immunotherapy as immune checkpoint stimulators. However, nothing so far is approved by the FDA that gives a positive signal to the T cells,” Shirwan said. “The immune checkpoint inhibitors take the foot off the brake, so to speak. This ligand, as an immune checkpoint stimulator, puts the gas on the immune system to destroy the tumor.

“Another big surprise is that an antibody to the same receptor targeted by SA-4-1BBL did not protect against tumors, demonstrating unique and desired features of SA-4-1BBL for caner immunoprevention.”

Shirwan and Yolcu plan to conduct further tests for SA-4-1BBL in cancer immunoprevention.

“Although the notion of cancer immunoprevention is an attractive one, the design of clinical trials presents a challenge with respect to the target population,” Shirwan said. “However, with advances in cancer screening technologies and genetic tools to identify high-risk individuals, we ultimately are hoping to have the opportunity to test the SA-4-1BBL molecule for immunoprevention in individuals who are predisposed to certain cancers, as well as in the presence of precancerous lesions.”

###

To encourage and accelerate research in cancer prevention, the National Institutes of Health have created a network for research into immunoprevention, outlining possible methods for testing promising preventive substances and provided opportunities for associated funding. The Immuno-Oncology Translational Network is designed to create a fertile environment for research and to facilitate cancer immunoprevention research projects focusing on people who are genetically predisposed to certain cancers, those who have been diagnosed with pre-malignant lesions or polyps, and individuals exposed to cancer-causing substances, such as smokers and asbestos workers.

#WeAreUofL

DISCLAIMER: Shirwan and Yolcu have ownership in the start-up company, FasCure Therapeutics, LLC, which has an option to license SA-4-1BBL from the University of Louisville for commercial development.

Media Contact
Betty Coffman
[email protected]
502-852-4573

Original Source

http://www.uoflnews.com/releases/immune-stimulant-molecule-shown-to-prevent-cancer/

Related Journal Article

http://dx.doi.org/10.1158/0008-5472.CAN-19-2401

Lehigh University CEE professor Dan M. Frangopol elected into Canadian Academy of Engineering as International Fellow

Dan M. Frangopol, the inaugural Fazlur R. Khan Endowed Chair of Structural Engineering and Architecture at Lehigh University, has been elected into the Canadian Academy...

SwRI develops new model, controller to optimize fast charging of electric vehicles

Technique averts potentially damaging “lithium plating,” accelerates recharge by 35%SAN ANTONIO — March 17, 2021 — Engineers at Southwest Research Institute are using internal...

VTT’s miniature hyperspectral camera launched to space in Aalto-1 satellite

VTT's small and lightweight hyperspectral camera was successfully launched to space in Aalto-1 nanosatellite on 23rd of June 2017. Scalable sensing technology offers opportunities...

Teva presents latest data on AJOVY® ▼ (fremanezumab) at EHF Congress

AMSTERDAM, NETHERLANDS – Teva Pharmaceutical Europe B.V. has presented results from a pooled analysis of three randomized, double-blind, placebo-controlled Phase 3 studies assessing AJOVY®...

FIU scientists discover how arsenic builds up in plant seeds

IMAGE: This image shows an Arabidosis plant ovelaying rice grains that spell out arsenic because this research predicts that this is how arsenic gets...

62 percent of Thais lack sufficient colorectal cancer awareness | BGI Insight

Colorectal cancer (CRC) is the fourth most common cancer and accounts for 11% of the cancer burden in Thailand in 2020, with over 21,000...

Study identifies the best healthy eating nudges

Study of real-life experiments from many disciplines shows the most effective ways restaurants and grocery stores can influence healthy eatingFontainebleau (France), Singapore, Abu Dhabi,...

How cells keep growing even when under attack

New findings on how stress leads to pathway diversion, putting resources into growthAMHERST, Mass. – In an unexpected new finding, biochemists at the University...

Suicide prevention in COVID-19 era

What The Article Says: COVID-19 presents a new and urgent opportunity to focus political will, federal investments, and global community on the vital imperative of...